Sabra Health Care REIT, Inc. (SBRA)
NASDAQ: SBRA · Real-Time Price · USD
17.90
-0.29 (-1.59%)
At close: May 12, 2025, 4:00 PM
17.90
0.00 (0.00%)
After-hours: May 12, 2025, 6:03 PM EDT
Sabra Health Care REIT Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Sabra Health Care REIT stock have an average target of 19.57, with a low estimate of 18 and a high estimate of 20. The average target predicts an increase of 9.33% from the current stock price of 17.90.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sabra Health Care REIT stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 2 | 1 | 1 | 1 | 1 |
Buy | 1 | 2 | 3 | 3 | 3 | 3 |
Hold | 2 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Scotiabank | Scotiabank | Hold Maintains $18 → $19 | Hold | Maintains | $18 → $19 | +6.15% | May 12, 2025 |
Truist Securities | Truist Securities | Hold Maintains $17 → $18 | Hold | Maintains | $17 → $18 | +0.56% | Mar 18, 2025 |
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $20 | Buy | Reiterates | $20 | +11.73% | Feb 21, 2025 |
Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $18 → $17 | Strong Buy → Hold | Downgrades | $18 → $17 | -5.03% | Jan 17, 2025 |
JMP Securities | JMP Securities | Hold → Buy Upgrades $20 | Hold → Buy | Upgrades | $20 | +11.73% | Jan 7, 2025 |
Financial Forecast
Revenue This Year
745.41M
from 702.64M
Increased by 6.09%
Revenue Next Year
780.76M
from 745.41M
Increased by 4.74%
EPS This Year
0.72
from 0.54
Increased by 33.57%
EPS Next Year
0.79
from 0.72
Increased by 9.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 798.2M | 844.2M | 899.9M | ||
Avg | 745.4M | 780.8M | 807.9M | ||
Low | 690.4M | 706.3M | 722.8M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 13.6% | 13.2% | 15.3% | ||
Avg | 6.1% | 4.7% | 3.5% | ||
Low | -1.7% | -5.2% | -7.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 0.80 | 0.88 | 0.86 |
Avg | 0.72 | 0.79 | 0.82 |
Low | 0.67 | 0.72 | 0.77 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 47.8% | 22.3% | 8.6% |
Avg | 33.6% | 9.9% | 3.6% |
Low | 23.4% | -0.8% | -2.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.